The serum pentraxin-3 is elevated in patients with cardiac syndrome X

Turk Kardiyoloji Dernegi Arsivi

Volumn 41, Issue 4, 2013, Pages 290-295

  Büyükkaya, Eyüp ^a   Karakaş, Mehmet Fatih ^a   Kurt, Mustafa ^a   Motor, Sedat ^a   Akçay, Adnan Burak ^a   Büyükkaya, Şule ^b   Karakaş, Esra ^a   Şen, Nihat ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b ANTAKYA STATE HOSPITAL   (Turkey)

Author keywords

Angina pectoris etiology; C reactive protein; Cardiac syndrome X; Coronary angiography; Coronary artery disease; PTX3 protein; Syndrome

Indexed keywords

PENTRAXIN 3; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM AMYLOID P;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYNDROME X; TREADMILL EXERCISE; BLOOD; COMPLICATION; METABOLISM; MIDDLE AGED; RADIOGRAPHY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MICROVASCULAR ANGINA; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 84879270641     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2013.20025     Document Type: Article

References (28)

1. Kemp HG Jr. Syndrome X revisited. J Am Coll Cardiol 1991;17:507-8.
2. Kemp HG, Kronmal RA, Vlietstra RE, Frye RL. Seven year survival of patients with normal or near normal coronary arteriograms: a CASS registry study. J Am Coll Cardiol 1986;7:479-83. (Pubitemid 16164373)
3. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993;328:1659-64. (Pubitemid 23157347)
4. Quyyumi AA, Cannon RO 3rd, Panza JA, Diodati JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 1992;86:1864-71.
5. Vane JR, Anggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36. (Pubitemid 20209469)
6. Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 2001;24:301-4. (Pubitemid 32285312)
7. Cosín-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patients with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003;41:1468-74. (Pubitemid 36543361)
8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
9. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 2001;54:316-22. (Pubitemid 32162036)
10. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-50. (Pubitemid 34016204)
11. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41. (Pubitemid 30640663)
12. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349-54. (Pubitemid 39407338)
13. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-7. (Pubitemid 32641804)
14. Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
15. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007;27:161-7. (Pubitemid 46360394)
16. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81. (Pubitemid 350234768)
17. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011;57:861-9.
18. Saygi S, Kirilmaz B, Tengiz İ, Türk UÖ, Yildiz H, Tuzun N, et al. Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting. Turk Kardiyol Dern Ars 2012;40:205-12.
19. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J 2012;163:274-9.
20. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006;45:326-30. (Pubitemid 44765293)
21. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009;227:9-18.
22. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010;210:220-5.
23. Sen N, Poyraz F, Tavil Y, Yazici HU, Turfan M, Hizal F, et al. Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. Atherosclerosis 2009;204:e82-5.
24. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-6. (Pubitemid 30657516)
25. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55. (Pubitemid 351619875)
26. Jaillon S, Peri G, Delneste Y, Frémaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007;204:793-804. (Pubitemid 46631609)
27. Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem 2010;285:17681-92.
28. Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez-Correa G, Bottazzi B, et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005;25:1837-42. (Pubitemid 41243451)